FDA Approval Genetic Disease In-Vitro Protein 
The Pharma Data
DECEMBER 20, 2020
The FDA approval of Klisyri is a significant milestone for Athenex,” said Johnson Lau, chairman and chief executive officer of Athenex. Approval demonstrates our ability to execute upon the entirety of the drug development and registration process. The FDA completed a class 2 response in July 2020.
Drug Discovery World
FEBRUARY 22, 2024
Dementia is the only major cause of death without a treatment to prevent, slow or stop disease progression. “In With the breadth and range of central nervous system disorders – for example Parkinson’s disease and multiple sclerosis – facing the global population there is an unmet need within this area of drug discovery.
Expert insights. Personalized for you.
52 
Let's personalize your content